MONROVIA, Calif. --(BUSINESS WIRE)--Feb. 16, 2022-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases, today announced that it will provide a corporate
-- Management to Host Conference Call at 4:30 p.m. ET Today -- MONROVIA, Calif. --(BUSINESS WIRE)--Feb. 23, 2022-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today
MONROVIA, Calif. --(BUSINESS WIRE)--Mar. 8, 2022-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will present preclinical data on two novel XmAb ®
MONROVIA, Calif. --(BUSINESS WIRE)--Apr. 8, 2022-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the presentation of new data from its preclinical-stage
MONROVIA, Calif. --(BUSINESS WIRE)--Apr. 28, 2022-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that it will release first quarter 2022 financial results
-- Management to Host Conference Call at 4:30 p.m. ET Today -- MONROVIA, Calif. --(BUSINESS WIRE)--May 5, 2022-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported
MONROVIA, Calif. --(BUSINESS WIRE)--May 26, 2022-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported initial dose-escalation data from the Phase 1 study evaluating
MONROVIA, Calif. --(BUSINESS WIRE)--Jul. 27, 2022-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will release second quarter 2022 financial results after
IRVING, Texas and MONROVIA, Calif. , Aug. 2, 2022 /PRNewswire/ -- Caris Life Sciences ® (Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize health care, and Xencor , Inc. (NASDAQ: XNCR), a clinical-stage
-- Management to Host Conference Call at 4:30 p.m. ET Today -- MONROVIA, Calif. --(BUSINESS WIRE)--Aug. 3, 2022-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported